TUMOR-DERIVED MITOGENIC ACTIVITY FOR TUMOR-INFILTRATING LYMPHOCYTES
肿瘤浸润性淋巴细胞的肿瘤衍生有丝分裂活性
基本信息
- 批准号:3811177
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
The idea that the tumor environment is intrinsically immunogenic and
therefore contains lymphocytes with the potential to induce tumor regressio
has led to the use of tumor infiltrating lymphocytes (TILS) in clinical
trials. In this procedure lymphocytes are grown ex vivo directly from tumor
in the presence of the lymphokine interleukin 2 (IL-2); patients are
reinfused with their TILs after the latter have been expanded in culture fo
several weeks. Although TILs have shown in vivo efficacy, the
characteristics of the tumor environment which result in the existence of
TILs in vivo remain unclear. Two classes of stimuli -- one derived from
cell-cell contact between tumor cells and immunocytes and the other from
soluble factors secreted by tumor cells with receptors for them embedded in
immunocyte plasma membranes -- are believed to influence T-cell homing and
proliferation. Although IL-2 is a potent mitogen for T-cells (the phenotype
of TILs), its biosynthesis is mainly confined to immunocytes. In this study
the subject of soluble factors other than IL-2 secreted by tumor cell lines
as sources of stimuli for TIL proliferation is being addressed. As a
starting point for this work, the issue of whether a tumor cell line
established from a melanoma tumor could stimulate the growth of TILs derive
from melanoma masses was examined. After confirming the amplification
potential of three melanoma cell lines, a nonmelanoma line was tested for
the same bioactivity and found to be at least as potent a mitogenic source.
Mitogenic activity for TILs was found in supernatants from both melanoma an
nonmelanoma supernatants; hence, tumor-derived mitogenic activity for TILs
could be ascribed to secreted factors. Biochemical and biophysical studies
are underway to identify and characterize tumor-derived mitogenic factors
for TILS.
认为肿瘤环境具有内在的免疫原性和
因此含有有可能诱导肿瘤消退的淋巴细胞
已导致肿瘤浸润性淋巴细胞(TIL)在临床上的使用
审判。在这个过程中,淋巴细胞是直接从肿瘤体外培养出来的。
在淋巴因子白介素2(IL-2)存在的情况下;患者
在后者扩大培养后再灌流他们的TIL
几个星期。尽管TIL已经显示出体内的疗效,但
导致肿瘤存在的肿瘤环境的特征
体内的TIL仍不清楚。两类刺激--一类来自
肿瘤细胞与免疫细胞之间的细胞-细胞接触
肿瘤细胞分泌的可溶性因子及其受体
免疫细胞质膜被认为影响T细胞归巢和
扩散。尽管IL-2是一种强大的T细胞有丝分裂原(表型
TIL),其生物合成主要局限于免疫细胞。在这项研究中
肿瘤细胞系分泌IL-2以外的可溶性因子的研究
作为TIL扩散的刺激来源的问题正在得到解决。作为一名
这项工作的起点,是肿瘤细胞系是否
从黑色素瘤建立可以刺激TIL来源的生长
对黑色素瘤肿块进行检查。确认扩增后
三种黑色素瘤细胞系的潜能,一种非黑色素瘤细胞系被测试
同样的生物活性,并被发现至少是一个有效的有丝分裂来源。
在黑色素瘤和黑色素瘤的培养上清液中均发现TIL的有丝分裂活性
非黑色素瘤上清液;因此,肿瘤来源的TIL有丝分裂活性
可能归因于分泌因素。生化和生物物理研究
正在鉴定和表征肿瘤来源的有丝分裂因子
用于TILs。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
B PACKARD其他文献
B PACKARD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('B PACKARD', 18)}}的其他基金
ONCOIMMUNIN--NEW TUMOR-DERIVED IMMUNOREGULATORY FACTORS
癌免疫素--新的肿瘤源性免疫调节因子
- 批准号:
3792445 - 财政年份:
- 资助金额:
-- - 项目类别:
USE OF TIME-RESOLVED FLUORESCENCE TO DETERMINE INTRACELLULAR ION GRADIENTS
使用时间分辨荧光测定细胞内离子梯度
- 批准号:
3770353 - 财政年份:
- 资助金额:
-- - 项目类别:
相似海外基金
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10581488 - 财政年份:2022
- 资助金额:
-- - 项目类别:
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10332251 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
- 批准号:
444149 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Operating Grants
Utilizing intranasal immunization to induce a cytotoxic T lymphocyte response and reduce metastatic burden in the lung
利用鼻内免疫诱导细胞毒性 T 淋巴细胞反应并减少肺转移负担
- 批准号:
10090666 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Re-sensitization of immune checkpoint therapy resistant cancers to cytotoxic T-lymphocyte mediated killing
免疫检查点疗法耐药性癌症对细胞毒性 T 淋巴细胞介导的杀伤重新敏感
- 批准号:
412967 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Fellowship Programs
Mechanism for control of HIV-1 by cytotoxic T lymphocyte
细胞毒性T淋巴细胞控制HIV-1的机制
- 批准号:
17K10021 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding the regulation of cytotoxic T lymphocyte signalling and activity through single-cell genomics
通过单细胞基因组学了解细胞毒性 T 淋巴细胞信号传导和活性的调节
- 批准号:
MR/P014178/1 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Fellowship
Enhancing cytotoxic T lymphocyte (CTL) responses by directly loading CTL epitope vaccines onto MHC Class I complexes on the dendritic cell surface
通过将 CTL 表位疫苗直接负载到树突状细胞表面的 MHC I 类复合物上,增强细胞毒性 T 淋巴细胞 (CTL) 反应
- 批准号:
9299648 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Discovery of Cytotoxic T Lymphocyte-inspired Bacteria Machine for Cancer Therapeutic Use Based on Synthetic Biological Approach
基于合成生物学方法发现细胞毒性 T 淋巴细胞启发的用于癌症治疗的细菌机器
- 批准号:
15K14415 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Elucidation of molecular mechanism of SV40 VP1 capsid protein to induce aimed cytotoxic T lymphocyte against viruses and its application for vaccine formulation.
阐明SV40 VP1衣壳蛋白诱导针对病毒的细胞毒性T淋巴细胞的分子机制及其在疫苗制剂中的应用。
- 批准号:
26860112 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Young Scientists (B)